Page 179 - 2020_01-Haematologica-web

Outcome of adult t(6;9) AML
tive AML - results of an international meta-
analysis. Blood. 2007;110(11):761.
46. Visconte V, Shetty S, Przychodzen B, et al. Clinicopathologic and molecular character- ization of myeloid neoplasms with isolated t(6;9)(p23;q34). Int J Lab Hematol. 2017;
39(4):409-417.
47. Wattad M, Weber D, Döhner K, et al.
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31(6):1306-1313.
48. Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage
strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017;31(6):1306-1313.
49. Willemze R, Suciu S, Meloni G, et al. High- dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC- GIMEMA AML-12 trial. J Clin Oncol. 2014;32(3):219-228.
50. Prebet T, Bertoli S, Delaunay J, et al. Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor
acute myeloid leukemia. Haematologica.
2014;99(10):e185-e187.
51. Luskin MR, Lee JW, Fernandez HF, et al.
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016; 127(12): 1551-1558.
52. Röllig C, Bornhäuser M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the pro- posed reporting system. J Clin Oncol. 2011; 29(20):2758-2765.
haematologica | 2020; 105(1)
169